Equities analysts expect that Aravive, Inc. (NASDAQ:ARAV) will announce earnings of ($0.45) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aravive’s earnings. The lowest EPS estimate is ($0.53) and the highest is ($0.35). Aravive posted earnings of ($0.53) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The firm is scheduled to announce its next earnings results on Wednesday, May 5th.
On average, analysts expect that Aravive will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($1.64). For the next fiscal year, analysts forecast that the business will report earnings of ($2.12) per share, with EPS estimates ranging from ($2.57) to ($1.73). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Aravive.
Aravive (NASDAQ:ARAV) last issued its earnings results on Monday, March 15th. The company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.27. The firm had revenue of $5.69 million during the quarter.
ARAV stock traded down $0.26 during trading on Friday, hitting $5.18. 122,532 shares of the company’s stock traded hands, compared to its average volume of 216,844. The business has a fifty day simple moving average of $6.76 and a two-hundred day simple moving average of $5.98. The firm has a market capitalization of $101.84 million, a P/E ratio of -2.53 and a beta of 3.20. Aravive has a 1 year low of $4.27 and a 1 year high of $14.94.
Several institutional investors have recently bought and sold shares of ARAV. Rhumbline Advisers acquired a new position in Aravive during the 4th quarter valued at about $75,000. Trexquant Investment LP purchased a new stake in shares of Aravive during the fourth quarter worth about $105,000. Susquehanna International Group LLP increased its holdings in shares of Aravive by 1,213.9% during the fourth quarter. Susquehanna International Group LLP now owns 25,364 shares of the company’s stock valued at $143,000 after acquiring an additional 27,641 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Aravive in the 3rd quarter valued at approximately $183,000. Finally, Blair William & Co. IL acquired a new stake in Aravive in the 4th quarter worth approximately $203,000. 40.54% of the stock is owned by hedge funds and other institutional investors.
Aravive Company Profile
Aravive, Inc, a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer.
Read More: What is a Special Dividend?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.